Mainstay Capital Management LLC ADV Sells 4,054 Shares of McKesson Corporation $MCK

Mainstay Capital Management LLC ADV lessened its holdings in shares of McKesson Corporation (NYSE:MCK) by 49.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 4,188 shares of the company’s stock after selling 4,054 shares during the quarter. McKesson makes up 0.3% of Mainstay Capital Management LLC ADV’s portfolio, making the stock its 24th biggest position. Mainstay Capital Management LLC ADV’s holdings in McKesson were worth $3,235,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in MCK. Obsidian Personal Planning Solutions LLC grew its stake in McKesson by 2.9% in the third quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock valued at $346,000 after acquiring an additional 12 shares during the period. IAM Advisory LLC raised its position in shares of McKesson by 0.3% during the third quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock worth $3,019,000 after purchasing an additional 13 shares during the period. PDS Planning Inc lifted its holdings in shares of McKesson by 1.1% during the 3rd quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock valued at $934,000 after purchasing an additional 13 shares in the last quarter. Berkshire Asset Management LLC PA lifted its holdings in shares of McKesson by 4.6% during the 3rd quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock valued at $227,000 after purchasing an additional 13 shares in the last quarter. Finally, Goldstein Advisors LLC grew its position in shares of McKesson by 4.4% in the 3rd quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock valued at $258,000 after purchasing an additional 14 shares during the period. 85.07% of the stock is currently owned by institutional investors.

McKesson Stock Performance

Shares of McKesson stock opened at $920.48 on Thursday. The business’s 50 day simple moving average is $900.55 and its 200 day simple moving average is $830.63. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00. The firm has a market cap of $112.75 billion, a PE ratio of 26.47, a P/E/G ratio of 1.52 and a beta of 0.38.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion during the quarter, compared to the consensus estimate of $105.98 billion. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The business’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, equities research analysts predict that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be issued a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 annualized dividend and a yield of 0.4%. McKesson’s dividend payout ratio is presently 9.43%.

Wall Street Analyst Weigh In

MCK has been the subject of a number of research reports. Wall Street Zen cut McKesson from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. Wells Fargo & Company lifted their price target on shares of McKesson from $914.00 to $925.00 and gave the company an “equal weight” rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. upped their price target on shares of McKesson from $983.00 to $1,107.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Leerink Partners reissued an “outperform” rating and set a $1,085.00 price objective on shares of McKesson in a research report on Thursday, March 5th. Finally, Evercore restated an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $960.93.

Insider Transactions at McKesson

In other news, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. This trade represents a 10.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of McKesson stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 3,868 shares of company stock worth $3,743,820. 0.08% of the stock is owned by insiders.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.